Immune Thrombocytopenia (ITP)

ITP is an autoimmune disorder characterized by isolated thrombocytopenia (platelets <100k/µL) due to antibody-mediated platelet destruction and impaired production. Most adults experience chronic disease requiring individualized therapy based on bleeding risk.

Symptoms

• Petechiae, purpura, easy bruising
• Prolonged bleeding from cuts, gum bleeding, epistaxis
• Heavy menstrual bleeding
• Rare but serious: gastrointestinal or intracranial hemorrhage
• Many patients asymptomatic despite low platelet counts

Diagnosis

• Exclusion of other causes: CBC, smear (normal morphology), rule out anemia/neutropenia
• Assess for secondary causes: HIV, HCV, lupus, thyroid disease, medications
• Bone marrow biopsy not routinely required (useful in patients >60 or with atypical findings)
• Platelet antibody testing not routinely recommended (high false negatives)

Treatment Considerations

• Decision guided by platelet count, bleeding symptoms, comorbidities, lifestyle
• Treat when platelets <30k or symptomatic bleeding; higher threshold in pregnancy or surgery

First-Line Therapy

• Corticosteroids: prednisone or dexamethasone pulses
• IVIG or anti-D immunoglobulin for rapid platelet rise (e.g., pre-surgery)
• Platelet transfusions reserved for life-threatening bleeding (use with IVIG/steroids)

Second-Line & Chronic Therapy

• TPO receptor agonists: romiplostim (weekly injection), eltrombopag/avatrombopag (oral)
• Rituximab (anti-CD20) for durable responses
• Fostamatinib (SYK inhibitor) for refractory cases
• Splenectomy offers long-term remission in many but now delayed ≥12 months to allow medical therapy trials
• Combination regimens increasingly used to achieve treatment-free remission

Special Situations

• Pregnancy: prednisone/IVIG first-line; TPO-RAs used cautiously
• Anticoagulation: individualized risk/benefit; maintain platelets >50k when possible
• Vaccinations: recommended before splenectomy; avoid live vaccines during immunosuppression

Lifestyle & Support

• Avoid NSAIDs and platelet-impairing supplements (fish oil, ginkgo)
• Use soft toothbrush, electric razor, protective gear for sports
• Communicate platelet trends to dentists/surgeons
• Address fatigue/anxiety with counseling/support groups

Complications

• Bleeding events (GI, intracranial)
• Side effects of chronic steroids (diabetes, osteoporosis), TPO-RAs (thrombosis risk, hepatotoxicity)
• Infection risk with rituximab/splenectomy

Research & Future Directions

Research targets immune tolerance, FcRn blockade, novel oral agents, and biomarker-guided therapy.

Experimental & Emerging Treatments

• FcRn Inhibitors (efgartigimod, rozanolixizumab): Accelerate IgG degradation to reduce platelet autoantibodies.
• BTK Inhibitors: Modulate B-cell signaling in refractory ITP.
• CAR-T & CAAR-T: Engineered cells targeting B cells producing anti-platelet antibodies.
• Microbiome Modulation: Trials explore whether gut-targeted therapies can recalibrate immune tolerance.

Track ITP with Diagnoza.care

Stay on Top of Platelet Trends – Log platelet counts, bleeding symptoms, medications, transfusions, vaccinations, surgeries, and mental health; schedule hematology visits; capture side effects; and let the AI companion alert you when counts drop or treatments change.

---

Medical Disclaimer: Informational only. Follow your hematologist for diagnostic evaluation, risk-based treatment planning, and monitoring of therapy-specific adverse events. Sources: American Society of Hematology, International Society on Thrombosis and Haemostasis, Platelet Disorder Support Association